ImaginAb Inc., a US based clinical stage immuno-oncology imaging company has entered into a non-exclusive license and collaboration agreement with Roche. Under the terms of the agreement, Roche will use ImaginAb's novel minibody CD8 T cell imaging agent in immuno-oncology clinical trials for multiple types of cancers. Financial terms of the agreement were not disclosed.

ImaginAb's CD8 T cell imaging agent is designed to be used with PET scan technology to non-invasively determine changes in CD8 T cell tumor infiltrates induced by immunotherapy treatments. This investigational approach has the potential to guide the development of immunomodulatory agents and combinations by assessing whether a patient's immune system responds to such agents, thereby offering an early prediction of therapeutic response.

Ian Wilson, Chief Executive Officer of ImaginAb, said: "We are thrilled about our collaboration with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics. We believe our platform offers real potential to accelerate clinical development of next-generation immunotherapeutics and ultimately provides guidance for personalized use of mono or combination therapies for patients suffering from different types of cancer. This collaboration further expands the network of companies, clinical investigators, and PET centers utilizing our 89-Zr CD8 ImmunoPET technology, demonstrating the utility and value of this technology in the field of immuno-oncology."